Korean firm's COVID-19 jab gets WHO status

The World Health Organization (WHO) has granted WHO Emergency Use Listing (EUL) for the COVID-19 vaccine, SKYCovione, from South Korean company SK bioscience (KRX: 302440).

SKYCovione is a self-assembled nanoparticle vaccine targeting the receptor binding domain of the SARS-CoV-2 Spike protein for SARS-CoV-2. It was developed with the Institute for Protein Design (IPD) at the University of Washington School of Medicine and uses UK pharma major GSK’s (LSE: GSK) pandemic adjuvant.

"We will be committed to develop more vaccines to not just strengthen Korea's vaccine sovereignty, but also enable equitable access of the vaccine"The development of SKYCovione has also been supported by funding from the Bill & Melinda Gates Foundation and Coalition for Epidemic Preparedness Innovations (CEPI) with support from the European Union (EU)’s Horizon 2020 program.